At a glance
ClinicalIndex Comparison RecordN/ACompleted· 200 enrolled
Drug / intervention
Xpert HPV +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Z 1313 - Comparison of Point-of-care Molecular Tests and Visual Inspection With Acetic Acid for Cervical Cancer Screening in HIV-infected Women in Lusaka, Zambia
In Brief
An observational study evaluating Xpert HPV and OncoE6 for Cervical Cancer. Completed, enrolled 200 participants across 1 site.
Detailed Summary
This study will compare the test performance characteristics of visual inspection with acetic acid (VIA), Xpert HPV, and OncoE6 in HIV-infected women, to inform the possible inclusion of these molecular tests in future cervical cancer screening
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCervical Cancer
CountriesZambia
CollaboratorsNational Cancer Institute (NCI)
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartAug 2014
Primary CompletionJun 2015
First PostedFeb 2016
TodayJul 2026
First PostedFeb 23, 2016
Enrollment StartAug 1, 2014
Primary CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 10.4 years ago
Interventions
Xpert HPVdevice
Point-of-care HPV DNA PCR test
OncoE6device
Point-of-care E6 oncoprotein test